This antibody and others (APX005M Sotigalimab) have been associated with modest tumor responses with several treatment-related adverse events such as elevated liver aspartate aminotransferase/alanine aminotransferase, lymphopenia, thromboembolic events, and cytokine release syndrome (53, 54). This evidence concerns the gene GPT and Down syndrome.